Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States

Cost-effectiveness analysis of canagliflozin (CANA) versus dapagliflozin (DAPA) as an add-on to metformin (MET) in patients with type 2 diabetes mellitus (T2DM) in the united states

Value in Health ◽

10.1016/j.jval.2014.03.1448 ◽

2014 ◽

Vol 17 (3) ◽

pp. A248 ◽

Cited By ~ 4

Author(s):

C. Neslusan ◽

A. Teschemaker ◽

S. Martin ◽

M. Willis ◽

P. Johansen

Keyword(s):

Diabetes Mellitus ◽

United States ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Cost Effectiveness ◽

The United States ◽

Cost‐effectiveness analysis of empagliflozin versus sitagliptin as second‐line therapy for treatment in patients with type 2 diabetes in the United States

Diabetes Obesity and Metabolism ◽

10.1111/dom.14268 ◽

2020 ◽

Author(s):

Odette Reifsnider ◽

Anuraag Kansal ◽

Pratik Pimple ◽

Valerie Aponte‐Ribero ◽

Sarah Brand ◽

...

Keyword(s):

United States ◽

Type 2 Diabetes ◽

Cost Effectiveness ◽

The United States ◽

Second Line ◽

Second Line Therapy ◽

Effectiveness Analysis ◽

Line Therapy

Faculty Opinions recommendation of Tranexamic acid in the routine treatment of postpartum hemorrhage in the United States: a cost-effectiveness analysis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.736028641.793572950 ◽

2020 ◽

Author(s):

John Svigos

Keyword(s):

United States ◽

Cost Effectiveness ◽

Tranexamic Acid ◽

Postpartum Hemorrhage ◽

The United States ◽

Routine Treatment ◽

PND5 Cost-Effectiveness Analysis of Newborn Screening for Spinal Muscular Atrophy in the United States

Value in Health Regional Issues ◽

10.1016/j.vhri.2020.07.393 ◽

2020 ◽

Vol 22 ◽

pp. S75

Author(s):

R. Arjunji ◽

J. Zhou ◽

A. Patel ◽

M.L. Edwards ◽

M. Harvey ◽

...

Keyword(s):

United States ◽

Cost Effectiveness ◽

Spinal Muscular Atrophy ◽

Newborn Screening ◽

Muscular Atrophy ◽

The United States ◽

Cost-Effectiveness Analysis of rFVIIIFc Versus Contemporary rFVIII Treatments for Patients with Severe Hemophilia A Without Inhibitors in the United States

PharmacoEconomics - Open ◽

10.1007/s41669-021-00283-6 ◽

2021 ◽

Author(s):

Ash Bullement ◽

Emma S. Knowles ◽

Pronabesh DasMahapatra ◽

Talaha Ali ◽

Ron Preblick

Keyword(s):

United States ◽

Cost Effectiveness ◽

Hemophilia A ◽

The United States ◽

Severe Hemophilia ◽

Atezolizumab and bevacizumab combination compared with sorafenib as the first‐line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost‐effectiveness analysis in China and the United states

Liver International ◽

10.1111/liv.14795 ◽

2021 ◽

Vol 41 (5) ◽

pp. 1097-1104

Author(s):

Feng Wen ◽

Hanrui Zheng ◽

Pengfei Zhang ◽

Weiting Liao ◽

Kexun Zhou ◽

...

Keyword(s):

United States ◽

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Systemic Treatment ◽

The United States ◽

Unresectable Hepatocellular Carcinoma

First Line ◽

Effectiveness Analysis ◽

PDB3 COST-EFFECTIVENESS ANALYSIS OF INSULIN DETEMIR COMPARED TO NPH INSULIN IN PATIENTS WITH TYPE-2 DIABETES IN THE UNITED KINGDOM

Value in Health ◽

10.1016/s1098-3015(10)65946-3 ◽

2004 ◽

Vol 7 (6) ◽

pp. 735-736

Author(s):

I Smith ◽

AJ Palmer ◽

S Roze ◽

T Kennedy-Martin

Keyword(s):

Type 2 Diabetes ◽

United Kingdom ◽

Cost Effectiveness ◽

Insulin Detemir ◽

Nph Insulin ◽

The United Kingdom ◽

PDB32 A LONG-TERM Cost-Effectiveness Analysis of Treatments for Type 2 Diabetes in Portugal: Once-Weekly Semaglutide 1 MG Versus Once-Daily Empagliflozin 25 MG

Value in Health ◽

10.1016/j.jval.2020.08.629 ◽

2020 ◽

Vol 23 ◽

pp. S511

Author(s):

N. Hallén ◽

D. Carvalho ◽

C. Costa ◽

B. Hunt

Keyword(s):

Type 2 Diabetes ◽

Cost Effectiveness ◽

Once Daily ◽

Cost-Effectiveness Analysis of Brief and Expanded Evidence-Based Risk Reduction Interventions for HIV-Infected People Who Inject Drugs in the United States

PLoS ONE ◽

10.1371/journal.pone.0116694 ◽

2015 ◽

Vol 10 (2) ◽

pp. e0116694 ◽

Cited By ~ 4

Author(s):

Dahye L. Song ◽

Frederick L. Altice ◽

Michael M. Copenhaver ◽

Elisa F. Long

Keyword(s):

United States ◽

Cost Effectiveness ◽

Risk Reduction ◽

People Who Inject Drugs ◽

The United States ◽

Evidence Based ◽

Infected People ◽

The Cost-effectiveness Analysis of Nurse-Family Partnership in the United States

Journal of Health Care for the Poor and Underserved ◽

10.1353/hpu.2017.0134 ◽

2017 ◽

Vol 28 (4) ◽

pp. 1578-1597 ◽

Cited By ~ 6

Author(s):

Jinjing Wu ◽

Kelsey S. Dean ◽

Zohn Rosen ◽

Peter A. Muennig

Keyword(s):

United States ◽

Cost Effectiveness ◽

The United States ◽

Effectiveness Analysis ◽

Nurse Family Partnership ◽

Family Partnership ◽

The Cost